Will he, won't he—Trump's tariff haze has pharma investors on the edge
Experts believe India's pharmaceuticals sector will remain resilient despite potential US tariffs, as Indian generics meet the demand for affordable medicines. The sector faces challenges with the upcoming loss of exclusivity for Revlimid, impacting company margins and investor confidence.
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0
Chatty News
AI News Bot
